Weekly company factor report
RIGL Valuation, Quality and Momentum
Rigel Pharmaceuticals Inc
Current comparison
Latest company comparison
The scores rank this company against other measured companies in the selected market. Open each section to check the figures behind them.
Current factor profile
Valuation and financial-strength measures both rank above most companies in the selected market. Measured price variability is high and should be considered separately from the return figures.
Low valuation with strong finances
The company ranks at the 87th percentile for value and the 95th percentile for financial strength in this market.
Value supported by price performance
The value rank is 87/100 and the price-performance rank is 74/100. Both measures are above most companies in the selected market.
Reported earnings have weaker cash support
Return on equity is 76%, but an accruals ratio of 0.465 suggests that reported earnings have less cash support.
Four main ranks
Company profile
Completed weekly snapshots
How the ranks have changed
Ready-made approaches
Which screens include this company
Passing a screen means the latest completed snapshot meets that screen’s published rules. It is not a recommendation.
Continue the research
Check the supporting evidence
Open the price record, technical position, market group or other company research that is available for RIGL.
Price against company results
Value
A higher value rank means the shares are cheaper on the combined definitions relative to this market. Negative earnings or cash flow need separate attention.
Current reading
The P/E ratio is 2.7 times earnings, which is low on the page’s valuation scale. Free-cash-flow yield is 9.2%, providing cash support for the valuation.
Value measures compared
Raw multiples and yields
P/E history
P/E is shown only when trailing earnings are positive.
Research path
How to test this valuation
A low valuation is a starting point. These checks show whether the earnings base, cash flow and completed price record support it.
Profitability, cash and balance sheet
Financial strength
The rank combines several company measures. The chart and figures below keep profitability, leverage and cash conversion visible separately.
Current reading
Return on equity is 76%. Conservative balance sheet with D/E of 0.22. Accruals ratio of 0.465 is elevated — earnings quality may be lower than headline numbers suggest.
Financial measures compared
Profitability and leverage
Completed returns and variability
Price performance and risk
Returns show direction; volatility and drawdown show how uneven the path has been. Both are based on completed prices.
Current reading
Near-term vol (115%) is expanding vs long-term (58%) — risk is increasing.
Returns over several periods
Recent and one-year volatility
How long the current readings have persisted
| Measure | Current | Current run | Direction |
|---|---|---|---|
| OS Composite | 0.960 | Unchanged for 15 snapshots | deteriorating |
| Value %ile | 0.870 | Unchanged for 15 snapshots | deteriorating |
| Quality %ile | 0.950 | Unchanged for 15 snapshots | improving |
| Momentum %ile | 0.740 | Unchanged for 1 snapshots | deteriorating |
| F-Score | 6.000 | Unchanged for 0 snapshots | stable |
| Confidence | 0.970 | Unchanged for 15 snapshots | improving |
| Volatility | 0.583 | Unchanged for 15 snapshots | deteriorating |
Like-for-like context
Sector comparison
The company is compared with measured companies in Healthcare for the same completed factor week.
Company against sector
Valuation distance from sector
| Company | Combined | Value | Financial strength | Price performance |
|---|---|---|---|---|
| NUTX Nutex Health Inc | 99.0 | 94.0 | 98.0 | 95.0 |
| IRWD Ironwood Pharmaceuticals Inc | 99.0 | 97.0 | 97.0 | 98.0 |
| CGEN Compugen | 98.0 | 85.0 | 96.0 | 93.0 |
| THC Tenet Healthcare Corporation | 98.0 | 92.0 | 92.0 | 82.0 |
| MD Mednax Inc | 97.0 | 88.0 | 87.0 | 90.0 |
| AMN AMN Healthcare Services Inc | 97.0 | 96.0 | 65.0 | 93.0 |
| HRMY Harmony Biosciences Holdings | 97.0 | 90.0 | 98.0 | 76.0 |
| OSCR Oscar Health Inc | 96.0 | 88.0 | 77.0 | 91.0 |
Reported company accounts
Company figures
Quarterly and annual figures are kept separate. The dates below show the latest accepted reporting periods.
Quarterly figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Annual figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Definitions and source checks
Measures and data
Each figure is shown with its plain definition. Percentile ranks compare the company with the selected market for the same completed week.
Value measures · Price compared with earnings, sales, assets and cash flow
Financial strength · Profitability, cash conversion and balance-sheet measures
Price performance · Completed price returns over several periods
Growth and stability · Revenue, earnings history and capital returned to shareholders
Combined value measures · Several valuation measures ranked together; 1 is cheapest
Capital use and company classification · Funding, distributions and company-size classifications
Company research path · week ending 11 Sep 2026
Value supported by company results and completed price evidence
The main checks pass. The supporting research is ready for a full review.
The path reads company results, valuation, completed price evidence and risk in that order. A later strength does not cancel an earlier weakness.
- ✓ Data readyPassed · 100/100 Published factors, company figures and completed prices are available.
- ✓ Company recordPassed · 92/100 Checks profitability, cash support, balance-sheet measures and their direction.
- ✓ Relative valuePassed · 87/100 Checks whether the current valuation compares well with the selected market.
- ✓ Market supportPassed · 87/100 Checks completed price performance, relative strength, trend and buying pressure.
- ✓ Setup and riskPassed · 68/100 Checks whether the price structure is usable without ignoring volatility or drawdown.
- 6 Full reviewReview now Open the supporting company, market and risk research before making a decision.
Evidence used now
What moves the research path
Each block opens the report section containing the figures behind the score.
- Financial-strength rank 95/100
- F-Score 6/9
- 5 usable annual periods
- Value rank 87/100
- P/E 2.7×
- Free-cash-flow yield +9.2%
- Price-performance rank 74/100
- Six-month return +82.0%
- Relative strength +0.2
- Stage 2 · Advancing
- Stage 2 · Advancing
- Price at -6.4% of its 52-week high
- Completed price structure and risk combined
- One-year volatility 58.3%
- Recent volatility 114.7%
- 12-month drawdown -48.9%
Completed factor weeks
How the evidence has moved
All four lines are higher-is-better market ranks on the same 0–100 scale.
What the current evidence supports
- Company record scores 92/100.
- Relative value scores 87/100.
- Market support scores 87/100.
- Setup scores 68/100.
What still needs attention
- Risk check scores 48/100.
Next check
Review the company figures, sector context, price chart and risk evidence together.
This path uses completed records and is recalculated with each published factor week. It is a research sequence, not a trade instruction.
Supporting Sharemaestro research
Continue with the available evidence
Only research pages with data for RIGL are shown.